Sanofi: Lymphoma, Non-Hodgkin trials
The registry lists 20 Lymphoma, Non-Hodgkin studies with Sanofi as lead sponsor. 0 are open to participants now and 9 have results posted.
Phase 1 3Phase 2 13Phase 3 3Phase 4 1No phase 2(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Evaluation of Approved Weight-Based Dose Compared to Fixed Dose of Plerixafor in Patients With Non-Hodgkin's Lymphoma (NHL) Weighing Less Than 70 KilogramsCompletedNCT01164475Phase 4Results posted
- The Effect of Rituximab on Mobilization With AMD3100 (Plerixafor) Plus G-CSF in Patients With Relapsed or Refractory Non-Hodgkin Lymphoma (NHL) or Hodgkin Disease (HD)CompletedNCT00444912Phase 2Results posted
- AMD3100 (Plerixafor) With G-CSF in Poor Mobilizing Adult Patients Who Previously Failed Hematopoietic Stem Cell (HSC) Collection/AttemptsCompletedNCT00396331Phase 2Results posted
- AMD3100 (Plerixafor) Given to NHL and MM Patients to Increase the Number of PBSCs When Given a Mobilizing Regimen of G-CSFCompletedNCT00396266Phase 2Results posted
- AMD3100 (Plerixafor) in Multiple Myeloma (MM) or Non-Hodgkin's Lymphoma (NHL) Patients Predicted to be Unable to Mobilize With G-CSF AloneTerminatedNCT00395967Phase 2Results posted
- Treatment With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma and Multiple Myeloma PatientsCompletedNCT00322842Phase 2Results posted
- Mobilization of Stem Cells With AMD3100 (Plerixafor) and G-CSF in Non-Hodgkin's Lymphoma and Multiple Myeloma PatientsCompletedNCT00322491Phase 2Results posted
- Mobilization of Stem Cells With Plerixafor, Chemotherapy and G-CSF in Multiple Myeloma or Non-Hodgkin's Lymphoma PatientsCompletedNCT00322387Phase 2Results posted
- Mobilization of Stem Cells With AMD3100 (Plerixafor) in Non-Hodgkin's Lymphoma PatientsCompletedNCT00103610Phase 3Results posted
- Evaluation of Plerixafor Plus G-CSF to Mobilize and Collect 5×10^6CD34+ Cells/kg in Non-Hodgkin's Lymphoma (NHL) Patients for Autologous TransplantationCompletedNCT01767714Phase 3
- A Multi-centre, Open Label, Single-arm Study Intended to Further Investigate the Safety and Efficacy of Plerixafor as a Front-line Mobilisation Agent in Combination With G-CSF in Patients With Lymphoma or MM (Multiple Myeloma).CompletedNCT00838357Phase 3
- Long-Term Follow-up Study for Non-Hodgkin's Lymphoma Patients Who Received Study Treatment (Plerixafor or Placebo) in the AMD3100-3101 Study (NCT00103610).CompletedNCT00741325
- This is a Multi-center, Single Arm, Open Label Study Intended to Provide Expanded Access to Plerixafor for Patients With Non-Hodgkin's Lymphoma (NHL), Hodgkin's Disease (HD) or Multiple Myeloma (MM) Who Are to Receive Treatment With an Autologous Peripheral Stem Cell Transplant.No longer availableNCT00720603
- Evaluation of the Safety and Efficacy of the Addition of AMD3100 to a G-CSF Mobilization Regimen in Patients With Lymphoma (NHL and HD) and Multiple Myeloma (MM).CompletedNCT00665314Phase 2
- Aflibercept and Standard Chemotherapy (R-CHOP) in First Line of Non Hodgkin B-cell LymphomaCompletedNCT00644124Phase 1
- Efficacy and Safety Study of SH T 586 in Combination With Rituximab to Treat Low-Grade NHLCompletedNCT00311129Phase 2
- Efficacy and Safety Study of Oral Fludarabine Phosphate in Combination With Mitoxantrone as First Line Treatment in Follicular NHLCompletedNCT00185445Phase 2
- Rituximab Plus CAMPATH in Patients With Relapsed/Refractory Low-Grade or Follicular, CD20-positive, B-cell NHLTerminatedNCT00077961Phase 1/2
- Phase I/II Study of CAMPATH in Patients With Relapsing or Refractory Non-Hodgkin's LymphomaTerminatedNCT00051701Phase 1/2
- A Study of Mitoguazone Dihydrochloride in Patients With AIDS-Related Non-Hodgkin's LymphomaCompletedNCT00002348Phase 2